anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The incidence of gallstones has been increasing in recent years, up to 10-15% in developed countries, and is still increasing at a rate of 0.6% per year. It is estimated that common bile duct stones (CBDS) are present in about 10-20% of patients with symptomatic bile duct stones. Each year, common bile duct stones lead to acute complications such as biliary obstruction, cholangitis and acute pancreatitis in a large number of patients, seriously endangering their lives and health. In addition, Diagnosis Related Group (DRG) analysis shows that each episode of common bile duct stones costs $9,000, and acute pancreatitis that progresses from common bile duct stones can result in 275,000 hospitalizations annually, incurring $2.6 billion in costs and imposing a significant economic and health burden on society. Therefore, timely diagnosis of common bile duct stones and intervention for them is crucial. Endoscopic retrograde cholangiopancreatography (ERCP) is the method of choice for the diagnosis and treatment of CBDS, and guidelines recommend stone extraction for all patients with CBDS who are physically fit enough to tolerate ERCP operations. However, ERCP is a highly demanding and risky operation with the potential for serious complications such as PEP (incidence 2.6-3.5%). How to diagnose choledocholithiasis early and accurately, achieve timely intervention to improve prognosis, and avoid unnecessary medical operations to reduce risks are the challenges we are currently trying to solve.

The guidelines recommend ultrasound endoscopy (EUS) or magnetic resonance cholangiopancreatography (MRCP) to determine the presence of CBDS, depending on the local level of care, for patients in the intermediate-risk group for CBDS and for patients in the low-risk group whose physicians still have a high suspicion of CBDS. sensitivity. In addition, a cost-effectiveness analysis showed that MRCP would be the preferred test when the predicted probability of CBDS is less than 40%, while EUS is the preferred test when the predicted probability is 40%-90%. Compared to MRCP, EUS has a wide range of applicability but a steep learning curve. ASGE states that a minimum of 225 EUS operations are required to qualify, while the ESGE states that a minimum of 300 operations are required. However, this experience can only be gained at training centers that perform a large number of cases. Thus, the training of novice physicians in resource-limited areas is a huge challenge, which leaves a significant shortage of experienced ultrasound endoscopists with poor performance in the actual diagnosis of common bile duct stones, greatly limiting the popularity of ultrasound endoscopy.

The purpose of this study is to evaluate the effectiveness and safety of the proposed deep learning-based bile duct scanning system in improving the diagnostic accuracy of common bile duct stones and reducing the rate of missed gallstones during bile duct scanning by novice ultrasound endoscopists through a single-center, tandem, randomized controlled trial
In this study, the investigators will utilize a regimen combining low dose total body irradiation and rabbit ATG to facilitate stem cell transplantation (SCT) with human leukocyte antigen (HLA) matched related and unrelated donors. Based on the hypothesis that early treatment interventions have significant late effects in allogeneic SCT, a simple intervention, varying the duration of intense immunosuppression following SCT, will be investigated in this study. This may allow more robust recovery of donor immune system cells in the first two months following transplantation and eventually result in lower risk of cancer relapse, while maintaining effective graft versus host disease (GVHD) control. Patients will be randomly assigned to receive GVHD prevention therapy using one of two different immunosuppressive regimens with tacrolimus \& mycophenolate mofetil (MMF). Patients assigned to the investigational group will receive MMF for 15 days following SCT with growth factor support using granulocyte macrophage colony stimulating factor (GM-CSF) beginning on post-transplant day 4. Patients randomized to the standard treatment group will receive MMF for 30 days following SCT with cytokine support using granulocyte colony stimulating factor (G-CSF) beginning on post-transplant day 4. If one of these treatment groups demonstrates an improvement in donor immune cell recovery, there may be a slow increase in the likelihood of patients being assigned to that more successful treatment group. Eventually the two groups will be compared with respect to the likelihood of either relapse or GVHD developing.
1453527 Treating hair WELLA AG 20 Sept 1974 [22 Sept 1973] 41161/74 Heading A5B [Also in Divisions D1 and D2] Human hair is set with a polymer in the course of being permanently waved or straightened by a process comprising (1) pre-washing the hair with washing agent containing an alkali metal or ammonium sulphite, (2) thoroughly moistening the hair with an alkaline solution of a mercaptocarboxylic acid salt, (3) winding the hair onto open-work hollow curlers having an external diameter of 10-24 mm, rinsing with water after an adequate period of action and removing the excess water, (4) simultaneously or sequentially oxidising the hair with hydrogen peroxide solution and setting the hair with a polymer and finally (5) drying the hair and removing it from the curlers. The pre-wash medium may have a pH value of 6-7.5. The washing agent may be an anionic tenside e.g. an alkyl aryl sulphate or an alkyl aryl ether sulphate. The mercaptocarboxylic acid salt is preferably ammonium thioglycolate or thiolactate with a pH value of 7.5-9.6. The curling time is in the region 10-45 minutes. After rinsing the excess water may be removed with a towel or using a drying hood. The hydrogen peroxide solution is adjusted to an acid pH e.g. using orthophosphoric acid, pyroacemic acid or salicylic acid. The polymer may be a natural or synthetic substance and is preferably a copolymer of 60% vinyl pyrrolidone, 36% vinyl acetate and 4% dimethyl aminoethyl methacrylate. The oxidising medium may further contain cetyl trimethyl ammonium chloride or cetyl pyrrodinium chloride, ethanol or isopropanol a perfume oil, a non-ionic wetting agent, a violet dye and water, in addition to the optional presence of the fixing polymer.
In a cosmetic composition (A) consisting of a solid water-in-oil emulsion (i.e. an aqueous phase dispersed in a lipid phase), the lipid phase comprises at least one wax (I) of m.pt. 25-42[deg]C, in the form of crystallites having an aspect ratio of at least 2. Independent claims are included for the use of (I) as texturizing agents in the production of cosmetic compositions in solid water-in-oil emulsion form, where the m.pt. of (I) is not restricted to 25-42[deg]C if the composition contains more than 50 wt. % aqueous phase.
Knee osteoarthritis (KOA) is a leading cause of chronic knee pain and disability, with a lifetime prevalence of 45%. Treatment for symptomatic KOA includes physical therapy, oral anti-inflammatory medications and intra-articular steroid injections, with total knee arthroplasty (TKA) (or knee replacement) as the definitive treatment. Acute postoperative pain is common after TKA, leading to increased opioid consumption and increased hospital length of stay. Pain control following TKA has been investigated with interventions such as intrathecal morphine, nerve blocks, and periarticular joint injection (PAI). PAI and adductor canal block are well-established techniques used both in combination or in isolation in the management of postoperative pain for patients undergoing TKA. The aim of this study is to assess postoperative patient-reported quality of recovery after TKA with PAI and single shot adductor canal block with or without adductor canal catheter infusion.
The study will recruit 100 PD patients, and then these patients will be randomized to sulforaphane group or placebo group (50 patients per arm) for 24 weeks clinic trial. Participants will receive 24 weeks of either sulforaphane or placebo per day, in addition to the existing treatment. Baseline assessments include demographics, a comprehensive medical history, anthropometric measurements (weight and height), physical examination, and lab work. The motor symptoms and cognitive function will be assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) and MATRICS Consensus Cognitive Battery #MCCB#, respectively, at baseline, week 12 and week 24. The cranial MRI is examined at baseline and repeated at week 24. The primary outcomes will be the cognitive function improvement. Secondary outcomes include motor symptoms, biological data, MRI, safety and tolerability. During the study period, safety index including blood routine, liver and kidney function and adverse reactions report will be recorded.
Subjects in the intervention group received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
PURPOSE: To provide a peptide having the peptide fragment and the synthetic analog of thrombospondin exhibiting a thrombospondin-like activity and useful for the treatment of tumor, treatment of wound, vascularization, platelet aggregation inhibition, etc. CONSTITUTION: This peptide contains a fragment of human thrombospondin expressed by the formula, R1 -X1 -X2 -Cys-R2 (R1 is H, amino, acetyl, arginine residue, etc.; X1 and X2 are each an amino acid residue selected from among valine, threonine and serine, etc.; R2 is an amino acid residue having (protected) carboxyl terminal or its acid-type group) and its synthetic homolog. The peptide inhibits the metastasis of tumor cell, cell adhesion and platelet aggregation in the body of mammal by its adhesion activity and is useful as a diagnostic agent for the fusion of wound, etc. The peptide and homolog of thrombospondin have thrombospondin-like activity.
Participants are taking 1 tablet per day. All participants will start with 1 tablet and continue with 1 tablet for 2 weeks before increasing dose.
Heart failure is one of the leading causes of death, hospitalization and poor quality of life among Veterans. For many Veterans despite receiving maximal medical therapy for heart failure with reduced ejection fraction (HFrEF), their cardiac function and functional capacity markedly decreases and they develop delays and blocks in their intrinsic conduction system (i.e. left bundle branch block). These patients then meet criteria for cardiac resynchronization therapy (CRT), which has been shown to improve cardiac function. However, up to 40% of patients who undergo CRT do not experience the expected improvement in cardiac function or clinical improvement, and this is termed "non-response".

A critical limitation of traditional CRT is that the leads do not directly utilize the heart's intrinsic conduction tissue, called the His-Purkinje system. An extensive web of conduction tissue capable of transmitting the electrical signals all over the ventricles within milliseconds, the His-Purkinje system conducts electrical stimuli much faster than conduction through a usual myocardial cell. The left bundle branch is a component of the His-Purkinje system. As such, electrophysiologic therapies that directly activate the left bundle branch area (LBBAP) have emerged as possible solutions to the problem of non-response to CRT. Although data suggests that in patients with complete LBBB, LBBAP can better optimize electrical synchrony and improve cardiac function compared to traditional bi-ventricular CRT, the efficacy has not been studied in CRT non-responders.

Currently, the most frequently used technique for assessment of the left ventricle is echocardiography because it is widely available. However, several studies have demonstrated that cardiac MRI (CMR) is superior to echocardiography in measuring left ventricle ejection fraction, particularly in terms of interstudy reproducibility. Recent studies have also demonstrated CMR imaging to be safe even in patients with non-MRI-conditional pacemakers and defibrillators. Studies have also observed that patients undergoing MRI with non-MRI-conditional pacemakers or ICDs neither experienced device/lead failure nor were they at increased risk by undergoing MRI. Despite established safety of CMR in patients with cardiac devices, it is not being routinely performed because there are concerns that the devices will cause field inhomogeneity resulting in magnetic susceptibility artifacts and non-diagnostic image quality. However, these concerns are overcome by utilizing contemporary imaging protocols with gradient echo sequences as opposed to standard steady-state free precession. By using these new protocols for CMR in this study, the investigators aim to establish the feasibility of CMR to prospectively assess cardiac function at baseline and during follow-up in patients with cardiac devices (i.e. that the image quality in subjects with implantable devices is adequate and not undermined by image artifact).
In Treatment Sequence 1, Period 1 Day 1, subjects will be dosed with a single administration of OC in the form of 1 PORTIA (ethyinyl estradiol \[EE\] and levonorgestrel \[LN\]) or equivalent tablet, orally. OC (EE and LN) PK will then be assessed at pre dose and over 48 hours after OC dosing. Period 1 will be immediately followed by Period 2 with no washout. The 48 hours post-OC dose PK sample for Period 1 must be collected prior to receiving the first dose of PF 04965842 in Period 2. In Period 2, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK in Period 2 will be assessed at pre dose and over 48 hours after OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11.

In Treatment Sequence 2, Period 1, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK will be assessed at pre dose and over 48 hours following OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11. Subjects will then undergo a washout period of at least 10 days (Day -1 of Period 2 starts 10 days after Day 12 of Period 1). In Period 2 subjects will be dosed with a single OC administration on Day 1. OC PK will then be assessed at pre dose and over 48 hours after OC dose.
At the family's initial visit to the pediatric weight management program/clinic each parent/guardian and adolescent (if age 12 yrs. or older) will complete the survey tool. At 3 months, families will be asked to complete a follow up survey. This will be fielded at a visit for those returning to clinic or by phone/mail for those not returning.
To provide a medicine identifying system which enables automatization of medicine identification.SOLUTION: A medicine identifying system 100 is constituted of a medicine photographing device 200 and a computer 500. Medicine identifying software 600 is installed in the computer 500. At the time of performing medicine identification, a user first sets a medicine to be identified in the medicine photographing device 200. Next, the medicine photographing device 200 photographs the medicine by using an operation of the user with respect to the computer 500 as a trigger. A photographed image of the medicine is transmitted to the computer 500 as data. Then, the medicine identifying software 600 refers to a database on the basis of this image data to search the medicine.SELECTED DRAWING: Figure 1
Objective: This research was conducted as a randomized controlled, double-blind experimental study to determine the effect of topical lidocaine and benzocaine on patient's pain and injection satisfaction before peripheral intravenous catheter application.

Study Design: The study was completed with 120 individuals who were treated in the green area of a University Hospital Emergency Service and met the inclusion criteria of the study. Ethics committee approval, Turkey Pharmaceuticals and Medical Devices Agency clinical research permission, institutional permission and written informed consent from individuals were obtained in the study. In collecting research data; Case Report Form (ORF), Baseline Algometer (66 Lb / 30 Kg) and Informed Consent Form were used. Lidocaine Spray, Benzocaine Spray and Alcohol were used in research groups. Private health insurance was provided for all patients included in the study for complications arising from the procedure. The data obtained from the research were evaluated in computer environment using IBM SPSS Statistics 23.0 statistics package program.
The prevalence of obesity in Korea has steadily increased over the past decade, reaching 38.4% in 2021. Notably, the rate of class II- III obesity, defined as a body mass index (BMI) of 30 kg/m2 or higher, exceeded 7% in the same year. Since January 2019, the National Health Insurance Service (NHIS) has provided coverage for bariatric surgery (BS) for eligible patients. Coverage is available for individuals with a BMI of 35 kg/m2 or higher, or those with a BMI of 30 kg/m2 or higher who also have obesity-related comorbidities. Additionally, partial reimbursement is offered for BS in patients with type 2 diabetes mellitus who have BMI values between 27.5 and 30 kg/m2. From 2019 to 2022, the NHIS recorded 9,080 BS procedures, with sleeve gastrectomy being the most commonly performed. The average percentage of weight loss 198±99.7 days post-surgery was 17.9%, with 80.0% of patients losing more than 10% of their body weight. This article presents the trends in obesity and BS in Korea.
One-thousand women 55 years of age or older will be recruited to be screened through the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol. This involves the cardiovascular assessment of resting blood pressure, blood pressure response to 3-min of moderate intensity exercise and large and small arterial elasticity. The participants will be classified into risk categories based on these measures. The incidence of the following adverse cardiovascular outcomes will be assessed in the five-year period after screening in both groups: Ischemic heart disease, acute myocardial infarction, stroke, percutaneous coronary intervention, coronary bypass surgery, congestive heart failure, and hypertension.
The present invention relates to a silicone resin composition, a method for preparing the same, and a scar treatment agent comprising the same. More specifically, the silicone resin composition comprises a) 5 to 70 wt % of a silicone resin, b) 0 to 40 wt % of wax, c) 1 to 15 wt % of an emulsifier, d) 0.01 to 10 wt % of a drug, e) 0.01 to 10 wt % of an activator, f) 0 to 30 wt % of a UV blocking agent, g) 0 to 5 wt % of an antioxidant, h) 0 to 80 wt % of water, and i) 0.1 to 5 wt % of a preservative. According to the present invention, the silicone resin composition uses a biocompatible raw material harmless to a human body, and is convenient by being safely and smoothly spread without stickiness. Also, the silicone resin composition is rapidly dried, and forms a thin silicone film to form a scar protection and a moisture environment. The silicone resin composition is specialized for preventing and alleviating erythema or pigmentation of a scar by UV blocking and antioxidant efficacy. The absorption of a drug and an activator, which are active ingredients, is improved by a high occlusive property and skin softening. Thus, it is possible to more soften and flatten a scar compared to the related art, and a synergic effect is secured with respect to prevention, treatment, and alleviation of a scar. In addition, the silicone resin composition has excellent flexibility, waterproofing properties, and moisturizing properties.
The invention discloses aloe wine for reducing blood pressure and a manufacturing method thereof. The aloe wine is prepared from fresh aloe leaves and is health-care medicinal liquor having effects of treating hypertension and preventing hypertension recrudescence. The aloe wine for reducing blood pressure utilizes low-alcohol liquor as base liquor, utilizes fresh aloe leaves as main raw materials and utilizes honey as an auxiliary material. The manufacturing method comprises the following steps of cleaning 400 to 500g of the fresh aloe leaves, cutting the cleaned fresh aloe leaves by a mechanical or manual method, putting the cut aloe leaves into a container, adding 1500ml of the low-alcohol liquor into the container for immersion, adding 500mg of honey into the container, sealing the container by a container cover, carrying out preservation for 15 to 18 days, filtering to remove aloe slag in the low-alcohol liquor by gauze, and carrying out sealing preservation. The aloe wine for reducing blood pressure is a drug for oral administration. The aloe wine can be taken 2-3 times every day by adults and the adult takes 15-20ml of the aloe wine once. Aloe and honey are purely natural products so that the aloe wine for reducing blood pressure does not damage a human body, has a sweet taste and a green color, is transparent, and is convenient for drinking.
PURPOSE: A composition for preventing or treating dyshepatia which contains plantago formosana extract is provided to reduce side effects and virulence expression rate and to be biopcompatible. CONSTITUTION: A composition for preventing or treating dyshepatia contains plantago formosana extract. The dyshepatia is caused by Fe- NTA(Ferric nitrilotriacetate). The plantago formosana extract includes plantamajoside as an active ingredient. An obtaining method of the plantago formosana comprises the following steps: obtaining alcoholic extract of plantago formosana and pulverizing thereof; and obtaining plantago formosana by performing gel filtration chromatography on butanol fraction. A pharmaceutical composition for dyshepatia prevention or treatment includes plantago formosana extract.
Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the right upper deltoid muscle. Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.
Risk Summary

Data from published literature report the presence of bupropion and its metabolites in human milk (see Data). There are no data on the effects of bupropion or its metabolites on milk production. Limited data from postmarketing reports of bupropion use in lactating patients have not identified a clear association of adverse reactions in the breastfed infant.

Neurotoxicity findings were observed in juvenile rats treated with a combination of dextromethorphan/quinidine on postnatal day (PND) 7, which corresponds to the third trimester of gestation through the first few months of life and may extend through the first three years of life in humans [see Use in Specific Populations (8.1)]. It is not known whether dextromethorphan is present in human milk. There are no data on the effects of dextromethorphan on the breastfed infant or the effects on milk production. Because of the potential for neurotoxicity, advise patients that breastfeeding is not recommended during treatment with AUVELITY and for 5 days following final dose.

Data

In a lactation study of 10 women, levels of orally dosed bupropion and its active metabolites were measured in expressed milk. The average daily infant exposure (assuming 150 mL/kg daily consumption) to bupropion and its active metabolites was 2% of the maternal weight-adjusted dose. Postmarketing reports have described seizures in breastfed infants. The relationship of bupropion exposure and these seizures is unclear.